New York, December 20, 2013 -- Moody's Investors Service commented that Jazz Pharmaceutical's announced acquisition of Gentium Sp.A. is credit negative because of the high purchase price relative to near-term EBITDA contribution. Jazz will pay $57 per share for Gentium, or roughly $1 billion, for an EBITDA contribution of $20 to $30 million in 2014. Jazz is rated Ba3 with a stable rating outlook and Gentium is unrated.
Vollständigen Artikel bei Moodys lesen
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.